CA2049342A1 - Formulations for stabilizing of igm antibodies - Google Patents
Formulations for stabilizing of igm antibodiesInfo
- Publication number
- CA2049342A1 CA2049342A1 CA 2049342 CA2049342A CA2049342A1 CA 2049342 A1 CA2049342 A1 CA 2049342A1 CA 2049342 CA2049342 CA 2049342 CA 2049342 A CA2049342 A CA 2049342A CA 2049342 A1 CA2049342 A1 CA 2049342A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- igm
- sodium
- lyophilized
- igm antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32857989A | 1989-03-27 | 1989-03-27 | |
US328,579 | 1989-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2049342A1 true CA2049342A1 (en) | 1990-09-28 |
Family
ID=23281559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2049342 Abandoned CA2049342A1 (en) | 1989-03-27 | 1990-03-13 | Formulations for stabilizing of igm antibodies |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0465513A1 (ja) |
JP (1) | JPH04504253A (ja) |
CA (1) | CA2049342A1 (ja) |
WO (1) | WO1990011091A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05507924A (ja) * | 1990-07-03 | 1993-11-11 | アクゾ・エヌ・ヴエー | 免疫反応性化合物 |
JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
CA2097932A1 (en) * | 1991-10-11 | 1993-04-12 | Shojiro Yamazaki | Antibody containing composition |
ATE146359T1 (de) * | 1992-01-21 | 1997-01-15 | Stanford Res Inst Int | Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
AU2444899A (en) * | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
ES2332402T5 (es) | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
EP1428537B1 (en) * | 2001-08-29 | 2008-11-19 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparations containing antibody |
JP5290489B2 (ja) | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Igg抗体の安定な液体医薬製剤 |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
JP5322405B2 (ja) * | 2007-06-07 | 2013-10-23 | 小林製薬株式会社 | タンパク質含有組成物 |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
CA2976671C (en) | 2010-03-01 | 2021-01-12 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
AU2011293554B9 (en) | 2010-08-23 | 2015-03-19 | Xbiotech Inc. | Treatment for neoplastic diseases |
HUE048876T2 (hu) | 2011-05-09 | 2020-08-28 | Mayo Found Medical Education & Res | Rákos megbetegedések kezelése |
CA2838964C (en) * | 2011-07-05 | 2021-07-13 | Novozymes Biopharma Dk A/S | Albumin formulation and use |
MX356808B (es) | 2011-09-23 | 2018-06-14 | Xbiotech Inc | Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia. |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
EA201692502A1 (ru) | 2014-06-16 | 2017-09-29 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Лечение миелом |
SI3204413T1 (sl) * | 2014-10-06 | 2020-07-31 | Mayo Foundation For Medical Education And Research | Sestave protiteles prenašalca ter metode za njihovo izdelavo in uporabo |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
JP6921802B2 (ja) * | 2015-08-18 | 2021-08-18 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research | キャリア結合剤組成物およびそれを作製および使用する方法 |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
CA3035378A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Carrier-pd-l1 binding agent compositions for treating cancers |
CN109843336A (zh) | 2016-09-01 | 2019-06-04 | 梅约医学教育与研究基金会 | 用于靶向t细胞癌症的方法和组合物 |
US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
EP3510048A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Methods of treating pd-l1 expressing cancer |
WO2018048958A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1546177A (en) * | 1976-11-19 | 1979-05-16 | Biokema Sa | Process for the preparation of a stable injectable solution |
JPS5822085B2 (ja) * | 1977-07-19 | 1983-05-06 | 株式会社ミドリ十字 | 静注用ガンマ・グロブリン製剤 |
DE3875852T2 (de) * | 1987-08-10 | 1993-03-18 | Miles Inc | Gereinigtes igm. |
-
1990
- 1990-03-13 CA CA 2049342 patent/CA2049342A1/en not_active Abandoned
- 1990-03-13 WO PCT/US1990/001383 patent/WO1990011091A1/en not_active Application Discontinuation
- 1990-03-13 JP JP50510090A patent/JPH04504253A/ja active Pending
- 1990-03-13 EP EP19900905158 patent/EP0465513A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0465513A1 (en) | 1992-01-15 |
JPH04504253A (ja) | 1992-07-30 |
WO1990011091A1 (en) | 1990-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2049342A1 (en) | Formulations for stabilizing of igm antibodies | |
Sarciaux et al. | Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying | |
EP0417193B1 (en) | Freeze-dried formulation for antibody products | |
Kerwin et al. | Effects of tween 80 and sucrose on acute short-term stability and long-term storage at− 20 C of a recombinant hemoglobin | |
AU695084B2 (en) | Formulations for factor IX | |
US4496537A (en) | Biologically stable alpha-interferon formulations | |
US9463241B2 (en) | Method for stabilising an immunoglobulin G composition in liquid form | |
AU600246B2 (en) | Stabilised human tissue plasminogen activator compositions | |
US20220257763A1 (en) | Room temperature stable lyophilized protein | |
US20100056765A1 (en) | Formulations That Inhibit Protein Aggregation | |
BR112012012080B1 (pt) | Formulações de histidina-trealose do anticorpo t1h | |
EP0417191B1 (en) | Formulation for antibody reagents | |
JPS6191131A (ja) | 医薬品の吸着防止方法および組成物 | |
US8372798B2 (en) | High-concentration protein formulations and method of manufacture | |
KR20040018458A (ko) | Cetuximab 및 폴리옥시에틸렌 소르비탄 지방산에스테르를 포함하는 액형 제제 | |
AU676833B2 (en) | Pharmaceutical compositions containing IL-6 | |
JPH11502205A (ja) | hCG液体製剤 | |
KR900004799B1 (ko) | 안정한 감마 인터페론 제제 및 이의 제조방법 | |
KR20200143449A (ko) | 메글루민 염을 사용하여 단백질을 포함하는 제형을 안정화시키는 방법 | |
JP2005508992A (ja) | 凍結乾燥されたモノクローナル抗体組成物 | |
JPH0137118B2 (ja) | ||
RU2136313C1 (ru) | Стабилизирующий состав для получения референс-сывороток, содержащих igm-антитела | |
WO2021141789A1 (en) | Stable formulations of anti-cancer peptides | |
JPS6399022A (ja) | 静脈内投与に適したガンマ・グロプリン | |
AU2002337895A1 (en) | Lyophilized monoclonal antibody compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |